Folic Acid Awareness Week (Sept 13–19, 2026) highlights the role of daily folic acid supplementation for women of reproductive age to reduce the risk of birth defects. The guidance emphasizes that dietary intake alone is often insufficient to meet recommended folate levels for prevention of neural tube defects and other congenital anomalies.
Folate (vitamin B9) is essential for DNA replication, repair, and normal cell growth, functions that are critical during early fetal development. Dietary sources of folate include dark green leafy vegetables, beans, peas, nuts, liver, and folate-containing fruits such as oranges, lemons, bananas, melons, and strawberries.
Most over-the-counter multivitamins contain folic acid, the synthetic and more bioavailable form of folate. The recommended daily amount of dietary folate equivalents for adults is 400 mcg; for pregnant women it is 600 mcg. Synthetic folic acid is more bioavailable than naturally occurring food folate—at least about 85% bioavailable for folic acid versus approximately 50% for natural food folate—making supplements and fortified foods important tools to achieve recommended intake.
Inadequate maternal folate during the periconceptional period and early pregnancy is associated with increased risk of neural tube defects (NTDs) such as spina bifida and anencephaly. The article reports that roughly 70% of neural tube defects could be prevented with appropriate folic acid supplementation.
Beyond NTDs, low maternal folate levels and insufficient folic acid use have been linked to a broader range of congenital anomalies, including certain congenital heart defects, urinary tract defects, oral facial clefts, and limb-reduction anomalies. Observational research indicates that adequate folate status and consistent folic acid use before and during early pregnancy are associated with reduced risks for some of these outcomes.
Since 1998, the U.S. Food and Drug Administration’s requirement to add folic acid to many enriched grain products has been followed by a substantial population-level decline in NTDs—national data cited in the source indicate about a 65% reduction in neural tube defect prevalence after fortification.
Current evidence suggests that autism spectrum disorders (ASD) reflect events that occur during pregnancy, with both genetic and non-heritable risk factors contributing. Maternal nutrition, including folate intake during the periconceptional period, has been studied as a potential modifiable factor.
The source summarizes findings from several observational studies—case-control and cohort designs—showing that maternal folic acid or multivitamin use around conception and in early pregnancy was associated with a lower risk of ASD in some populations. Examples cited include the CHARGE case-control study and the Norwegian Mother and Child Cohort Study (MoBa). A Swedish study (2017) is mentioned in which maternal multivitamin use was associated with lower odds of having a child with ASD with intellectual disability (reported odds ratio in the original source).
The article notes that not all studies are concordant and that factors other than folic acid may explain observed associations. It emphasizes that risks associated with multivitamin or folic acid use are low while potential benefits are meaningful, supporting current recommendations despite uncertainties about direct causation.
All major U.S. public health organizations referenced in the source—CDC, ACOG, and the USPSTF—recommend that all persons who could become pregnant take a daily supplement containing 400–800 mcg of folic acid. These recommendations have been reaffirmed in recent years (the source cites USPSTF 2023 and CDC 2025 statements).
Most standard multivitamins contain about 400 mcg (0.4 mg) folic acid, and most prenatal vitamins contain about 800 mcg (0.8 mg). The article reiterates that these amounts match commonly available products and current guideline ranges for prevention of neural tube defects and other folate-sensitive outcomes.
Because an estimated 50% of pregnancies are unplanned, the article emphasizes that any woman who could become pregnant should take folic acid daily even if she is not actively planning a pregnancy. Folic acid is critical during the first weeks of pregnancy, a period when many women may not yet be aware they are pregnant.
The source also highlights that starting folic acid at least one month before conception has been associated with decreased risk for ASD in some studies, whereas initiating supplementation after conception may not provide the same potential benefit for certain outcomes.
Certain women may need higher-than-standard folic acid doses or consideration of folate-related compounds (for example, l-methylfolate). The source identifies groups at increased risk for folate deficiency or impaired folate status, including:
The source states that guidelines on specific dosing for many of these higher-risk groups are not well-established and refers readers to specific clinical guidance articles for detailed recommendations.
For women with a prior pregnancy affected by a neural tube defect, the source reports the recommended preventive dose is 4,000 mcg (4 mg) of folic acid daily beginning at least one month before conception and continued through the first trimester.
Public health authorities (CDC, U.S. Public Health Service, ACOG) urge every woman who could become pregnant to take at least 400 mcg (0.4 mg) of folic acid daily. Most multivitamins provide about 400 mcg and most prenatal vitamins about 800 mcg. Because many pregnancies are unplanned and folic acid is needed in early embryogenesis, daily supplementation beginning before conception is recommended.
Clinicians should also be aware that women with untreated psychiatric illness are less likely to take prenatal vitamins; prescribing or counseling about medications for reproductive-age women presents an opportunity to discuss the importance of folic acid and encourage multivitamin or prenatal vitamin use.
The source lists CDC materials, population cohort and case-control studies (including CHARGE and MoBa), meta-analyses, and guideline publications. Specific references cited in the original article include CDC guidance on MTHFR and folic acid, cohort and case-control studies linking periconceptional folic acid to reduced ASD risk, meta-analyses on prenatal folic acid and ASD, studies on congenital heart defect associations, and professional guidelines addressing folic acid and multivitamin supplementation for prevention of folic acid–sensitive congenital anomalies.
(For full citation details, see the reference list in the original source.)